Medical Affairs can gather insights to identify clinically meaningful differentiators by engaging with the external community years ahead of launch. These insights can inform clinical strategy and a holistic evidence generation plan that will produce and enhance value substantiation. As the product progresses through its development cycle, the evidence generation priorities and opportunities of the product will evolve. At the prelaunch phase, generating registration data will be prioritized, whereas during launch, generating real world and economic evidence will become more prominent.
Top Reasons to Attend
- Understanding the Value of Real-World Evidence Throughout the Development Stages to Support a Product's Value
- Developing a Unique KOL Early Engagement Plan to Provide your Product a Critical Competitive Edge
- Involving a Qualified Medical Affairs Team from the Start to Execute a Designed Strategy and Achieve Medical Affairs Goals
- Implement a Well-Planned Strategy to Recruit, Engage and Manage your Medical Affairs Team Effectively.
- Improving Collaboration with R&D to Become a More Strategic Medical Affairs Partner
Who Should Attend
Pharma, biotech, and medical device company professionals with responsibilities in:
- Medical Science Liaison (MSL)
- Medical Affairs
- Early Stage Medical Affairs
- KOL Relationship Management/ Development
- Opinion/Thought Leader Relations
- External Engagement
- Chief Medical Officer
- Commercial Operations
- Medical and Professional Affairs/Strategy
- Medical and Professional Education
- Scientific/Medical Communication, Relations and Affairs
- MSLs
- Medical Communications
- Scientific Affairs
- Clinical Trials
- Clinical Affairs
- KOL Development
- Scientific Advisor
- Clinical Research
- Medical Education
- Clinical Investigation
- Regulatory Affairs
- Medical Science
- Medical Information Specialist
- Regulatory Affairs
- R&D
- Real World Evidence
Service Providers
- RWE Solution Providers
- CROs
- Consultancies
Networking Capabilities
- Virtual Matchmaking: Visit our virtual lobby and connect with fellow attendees using our platform's matchmaking technology. You can chat, video, and even make a list of the people you want to meet and the knowledge you're looking to gain through our bespoke 1:1 match-making services
- Roundtable Networking throughout the Summit will give you the chance to connect and meet in-depth your fellow attendees as well as our Sponsors and Speakers
- The platform we use allows us to make polls, QA, and chat during the sessions.
- Virtual Happy Hour: Grab a drink and bring it to your screen to cheers from afar while continuing to chat with and get to know your fellow conference participants.
Speakers
- Liliana Alfaya-Virzi, Med Director, IO, CELLECTIS
- Scott Baver, Senior Director, Pipeline Medical Affairs, APELLIS PHARMACEUTICALS
- Sanaz Cardoza, Medical Science Liaison, MALLINCKRODT PHARMACEUTICALS
- Dan Davis, Senior Director Oncology Medical Affairs, ELI LILLY
- Dennis Decktor, Director and Senior Director, Medical Affairs, NESTLE USA
- Arindam Dey, Clinical Development & Medical Affairs Head, ALCON
- Quinn Dinh, Medical Affairs & Pipeline Launch Strategy Vice President, International, HORIZON THERAPEUTICS
- Ashish Dugar, Global Senior VP, Head of Medical Affairs, DYNE THERAPEUTICS
- Anne Marie Greco, Global Director, Medical Affairs Early Portfolio, LEO PHARMA
- Katie Luepke, Senior Medical Science Liaison, HERON THERAPEUTICS
- Stephanie Macholtz, Senior Director, Ethics & Compliance, HEALTHCARE COMPLIANCE COUNSEL
- Dima Martini-Drew, Senior Medical Director, TA Specialty, ASTELLAS
- Barbara McGovern, Vice President Medical Affairs, SERES THERAPEUTICS
- Kristy Grimm Porter, Vice President, Global Medical Communications and Operations Global Medical, VERTEX PHARMACEUTICALS
- Loredana Regep, Vice President, Medical & Regulatory Affairs, ROCHE
- Oscar Segurado, Chief Medical Officer, ASC THERAPEUTICS
- Andrew Shim, Executive Director, Head of Global HEOR, Medical Affairs, TURNING POINT THERAPEUTICS
- Diana Stefani-Hunyady, Senior Medical Director, Medical Affairs, TURNING POINT THERAPEUTICS
- Megan Sutton, Medical Strategy-Cardiomyopathies, US Medical Affairs, BRISTOL MYERS SQUIBB
- Wendy Wells, Director, Medical Affairs Training, APELLIS PHARMACEUTICALS
Please fill in your name and email to receive the Virtual Summit Agenda of this event.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
